Regentis Biomaterials made a four-year deal with AMI Medical to sell its GelrinC implant for knee repairs in Israel.

Nov 11, 2026, 2:04 AM ETDealRead the original at newswire.com

Good for RGNT

The 4-year exclusive Israel deal gives Regentis a route to sales, backed by minimum purchase requirements, and GelrinC is approved there. Revenue is expected only in 2027, and its U.S.

RGNT · Regentis Biomaterials Ltd.

AI read · Good for RGNT

The AI's read

AMI's network of surgeons, hospitals, and clinics could help Regentis reach customers in Israel. GelrinC is already approved there, and the contract includes minimum purchase requirements. The benefit is still ahead: Regentis expects initial revenue in 2027, and its U.S. Phase III trial continues.

Get alerts for RGNT

Follow Regentis Biomaterials Ltd. (RGNT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RGNT

Free on the App Store and Google Play, or on the web.